Researchers classified the 95 post-COVID participants through objective olfactory testing and their clinical history. The COVID+OD group included 42 adults whose smell impairment had persisted for at least three months after infection. Each had scores below 13 out of 16 on both the Identification and Discrimination subtests of the Sniffin’ Sticks test, had no structural nasal pathology considered capable of explaining the dysfunction, and had no olfactory dysfunction that predated the infection. The COVID−OD group comprised 53 adults with no history or current olfactory dysfunction; each scored at least 13 on both subtests. Both groups required a documented, PCR-confirmed SARS-CoV-2 infection at least three months before inclusion and a negative antigen test at enrollment. Healthy controls reported normal olfaction, had no history of COVID-19 or relevant neurological disorders, and also had Identification and Discrimination scores of at least 13.

The biological measurement used an alpha-synuclein seeding-amplification assay, abbreviated aSyn-SAA, on olfactory-mucosa samples obtained by ear, nose and throat specialists. Swabs were collected medial to the middle nasal turbinate toward the superior nasal turbinate, refrigerated at 4 degrees Celsius and shipped on dry ice for processing at the University of Verona. In the assay, diluted tissue homogenate was combined with recombinant full-length human alpha-synuclein, a fluorescence-sensitive dye and small glass beads. Reactions were run in triplicate at 30 degrees Celsius, with periodic shaking and fluorescence measurement for up to 50 hours. A sample was classified as positive if at least two of three replicates crossed the prespecified fluorescence threshold. Samples with one positive replicate were reanalyzed and, if the pattern persisted, were classified as negative.

Among the 137 participants in the healthy-control and post-COVID groups, 28, or 20.4%, had detectable olfactory-mucosa alpha-synuclein seeding activity. Diagnostic group was associated with assay status in an overall chi-square test, with a small-to-medium effect size of Cramer’s V = 0.25. After correction for multiple comparisons, the COVID+OD group had a significantly higher positivity rate than both healthy controls and the COVID−OD group, with adjusted p values of 0.030 for each comparison. The COVID−OD and healthy-control groups did not differ significantly, with an adjusted p value of 0.65. In multivariable logistic regression, diagnostic group remained associated with positive assay status after adjustment for age and sex, whereas age and sex were not significant predictors. Participants with persistent post-COVID olfactory dysfunction had higher adjusted odds of positivity than either healthy controls or post-COVID participants without olfactory dysfunction.

The study did not conduct a formal power calculation because no suitable prevalence estimates were available for olfactory-mucosa assay positivity in post-COVID groups or healthy controls. Because consecutively recruited groups differed in age, the researchers also assembled a sensitivity cohort of 33 age- and sex-balanced participants per group. That balanced analysis repeated the clinical-outcome comparisons rather than explicitly repeating the seeding-status comparison. It reproduced the main clinical pattern: COVID+OD participants had lower Montreal Cognitive Assessment scores and higher Movement Disorder Society Unified Parkinson’s Disease Rating Scale total scores than healthy controls. Higher scores also remained evident in the Part I and Part III MDS-UPDRS components, while the group effect for Part II did not reach statistical significance in the reduced cohort.

Within the post-COVID cohort, olfactory performance was associated with alpha-synuclein seeding status. After adjustment for age and sex, participants with a positive olfactory-mucosa assay had lower odor Discrimination scores and lower odor Identification scores. The corresponding analyses produced p < 0.001 for discrimination and p = 0.007 for identification, with partial eta-squared values of 0.12 and 0.08. No statistically significant association was detected between seeding activity and MDS-UPDRS total or subcomponent scores, MoCA scores, or Innsbruck REM Sleep Behavior Disorder Inventory scores. The clearest clinical correlate measured in the study was therefore the degree of olfactory impairment, rather than parkinsonian symptoms, global cognitive performance or symptoms suggesting REM sleep behavior disorder.

Broader assessments also distinguished the COVID+OD group from healthy controls. COVID+OD participants had lower MoCA scores, with an adjusted post-hoc p value of 0.038, and higher MDS-UPDRS total scores, including p < 0.001 for the comparison with healthy controls and p = 0.015 for the comparison with COVID−OD participants. They also had higher scores in the MDS-UPDRS sections assessing non-motor experiences of daily living, motor experiences of daily living and the motor examination. The authors emphasized that the absolute motor scores were low and did not suggest clinically manifest parkinsonism. They further noted that the observed pattern was compatible with reports in which persistent post-COVID olfactory dysfunction co-occurred with fatigue, affective symptoms, sleep disturbance, psychomotor slowing and cognitive impairment, although those broader outcomes cannot be assigned a cause in this study.

The observations are consistent with the hypothesis that injury and inflammation involving the olfactory mucosa after SARS-CoV-2 infection may promote local alpha-synuclein misfolding or aggregation. The study notes that SARS-CoV-2 may reach the nervous system through olfactory routes and that experimental evidence cited by the authors indicates that viral neuroinvasion and inflammation can promote alpha-synuclein misfolding. Research on olfactory neurons from people with persistent post-COVID hyposmia has also identified ongoing inflammatory changes. Nevertheless, the present association does not establish a causal pathway. Alpha-synuclein seeding activity has been detected in olfactory mucosa in conditions associated with alpha-synuclein pathology, meaning the current data cannot distinguish a transient post-infectious molecular response from a possible early signature of synucleinopathy.

Several features constrain interpretation of the pilot results. The study was small and cross-sectional, and it did not longitudinally establish whether assay positivity persists, resolves, progresses or predicts Parkinson’s disease or another synucleininopathy. Recruiting healthy controls without prior SARS-CoV-2 exposure became increasingly difficult as infection exposure spread through the population. Some controls may have had unrecognized previous infections, an uncertainty compounded because nucleocapsid antibody testing, which can distinguish infection-related seroreactivity from vaccine-related immunity, was introduced only after healthy-control recruitment was completed. The differences in motor and cognitive scores could also reflect post-COVID sequelae, pre-existing prodromal neurodegenerative changes or an interaction between both processes. The findings indicate a cross-sectional association in a selected clinical sample, not a demonstrated increase in neurodegenerative risk. Prospective studies using serial olfactory-mucosa assays, dopaminergic imaging and additional fluid and tissue biomarkers would be required to determine the biological and prognostic meaning of a positive result.

Subject of Research: Pilot study of olfactory alpha-synuclein seeding activity after SARS-CoV-2 infection

Article Title: Prevalence of alpha-synuclein seeding activity in the Olfactory Mucosa following SARS-CoV-2 infection: results from a pilot study

Article References: Heim, B., Seppi, K., De Cleene, N., Bongianni, M., Bronzato, E., Cerejo, C., Jagusch, F., Kindl, P., Löffler-Ragg, J., Weiss, G., Gottfried, T., Schmutzhard, J., Zanusso, G., & Poewe, W. (2026). Prevalence of alpha-synuclein seeding activity in the Olfactory Mucosa following SARS-CoV-2 infection: results from a pilot study. Acta Neuropathologica, 152(1), Article 58. https://doi.org/10.1007/s00401-026-03104-4

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03104-4

Keywords: SARS-CoV-2, COVID-19, olfactory dysfunction, alpha-synuclein, seeding amplification assay, olfactory mucosa, Parkinson’s disease, neuroinflammation, smell loss, pilot study, Prevalence, seeding

The project, called Dynamic Ensemble-to-Rescue: Decoding and Controlling the IDR Molecular Grammar at Scale (DETR), will initially study Parkinson’s disease and Ewing sarcoma, a rare cancer of bone and soft tissue in children and young adults. Its investigators plan to develop three tools and resources: a cerebrospinal fluid test for the shape of alpha-synuclein, molecules designed to bind harmful forms of disordered proteins, and an open foundation model for studying thousands of disease proteins that do not have proven drug therapies.

Neurologist Xiaobo Mao, Ph.D., a professor of neurology at the Johns Hopkins University School of Medicine, created the project’s scientific vision and is serving as principal investigator. He assembled 21 investigators from 12 institutions in the United States and Europe. DETR is one of several efforts in ARPA-H’s BIOmolecular Grammar for protein Aggregation Modulation and Intervention program, which is intended to support earlier detection of protein misfolding and intervention before disease advances, particularly in neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease. Shannon Greene, Ph.D., leads the ARPA-H program.

The central problem is that a protein’s amino-acid sequence can be read quickly but may not reveal which three-dimensional shape a protein will adopt or whether that shape is harmful. Mao said that predicting a protein’s shape could support the design of drugs that recognize a harmful form while leaving a healthy form alone. This is the program’s scientific premise; the funded work has not yet established that such predictions, diagnostic tests or targeted molecules will work in patients.

DETR is organized around two technical areas spanning two 24-month phases. The first will seek to establish the molecular grammar of intrinsically disordered regions by examining how primary sequence, structural features and environmental conditions govern their behavior. The investigators plan to build a foundational model that integrates computational and experimental work, with high-throughput laboratory platforms producing measurements used to train and test it. These are proposed methods and development objectives, not findings from a completed experiment.

The second technical area will focus on detecting and controlling protein misfolding. For early detection, the investigators aim to identify misfolding that could function as a biomarker in diagnostic tests. The planned cerebrospinal fluid assay is intended to read the shape of alpha-synuclein, the protein associated with the deposits that define Parkinson’s disease, and could potentially identify the disease years before symptoms occur. That timing is a project goal rather than a demonstrated result of the award announcement.

For therapeutic development, the program’s stated aim is to restore a protein’s function or prevent aggregation and misfolding from beginning while leaving a working form untouched. A second intended resource is a class of molecules designed to bind harmful forms of disordered proteins while sparing healthy forms. The third is an open foundation model intended to allow laboratories to ask consistent questions about disease proteins that currently lack proven drug therapies. These outputs remain to be developed and evaluated.

Although the first studies will focus on Parkinson’s disease and Ewing sarcoma, the project is designed to produce foundational resources that may support research into other conditions. The announcement identifies possible applications including Alzheimer’s disease, cancer, heart disease, type 2 diabetes and infections that may remain dormant before reappearing years later. These are intended areas of future use; the protocol has not demonstrated detection or treatment for those conditions.

Johns Hopkins Medicine will serve as the prime institution guiding DETR, with eight additional Johns Hopkins laboratories taking part. The institutional partners also include Columbia University, the Gladstone Institutes, the Massachusetts Institute of Technology, the University of Michigan at Ann Arbor, Emory University, the University of Copenhagen, the Institute for Research in Biomedicine in Barcelona, the University of Texas at Austin, Arizona State University, the University of Texas at Dallas, and the University of Washington with the Seattle Institute for Biomedical and Clinical Research. Project outputs are planned for public sharing through open-access resources, but the award does not yet establish the accuracy, safety or clinical usefulness of the proposed tools.

Subject of Research: A planned multicenter research protocol on detecting and controlling disease-associated protein misfolding

Article Title: Johns Hopkins Medicine leads up to $52 million federal effort to study protein shapes and folding

Article References: Johns Hopkins Medicine leads up to $52 million federal effort to study protein shapes and folding. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: protein misfolding, ARPA-H, Johns Hopkins Medicine, Parkinson’s disease, Ewing sarcoma, alpha-synuclein, biomarker, foundation model, intrinsically disordered proteins, research protocol, Johns, Hopkins

The research, led by Professor Shohreh Majd and colleagues, focused on a molecular system called the ubiquitin-proteasome pathway, which functions as the cell’s garbage disposal. When proteins become damaged or misfolded, they are tagged with a small molecule called ubiquitin and shuttled to the proteasome, a barrel-shaped structure that shreds them into reusable fragments. In neurons affected by Parkinson’s disease, this system appears to slow down or stall entirely, allowing alpha-synuclein to pile up inside cells until it becomes toxic.

Using a combination of advanced microscopy and biochemical assays, the Danish team discovered that a specific protein complex, known as the 26S proteasome, becomes chemically altered in ways that impair its function in dopaminergic neurons, the very cells that die in Parkinson’s disease. These alterations, called post-translational modifications, act like rust on a machine, gradually degrading the proteasome’s ability to recognize and destroy its targets. The researchers found that one particular modification, the attachment of small ubiquitin-like molecules called SUMO proteins, was significantly elevated in affected neurons compared with healthy controls.

What makes this finding particularly striking is that the SUMOylation of the proteasome appears to be triggered by the very stress conditions that dopaminergic neurons face in Parkinson’s disease, including oxidative damage from reactive oxygen species and mitochondrial dysfunction. In other words, the disease environment itself may be sabotaging the cell’s ability to clean up after it. This creates a vicious cycle in which stress impairs protein clearance, which allows more toxic proteins to accumulate, which in turn generates more stress.

To test whether this cycle could be broken, the researchers used a small molecule designed to block the enzyme responsible for attaching SUMO proteins to the proteasome. When they applied this inhibitor to dopaminergic neurons grown in laboratory dishes, proteasome activity rebounded, and the accumulation of alpha-synuclein dropped substantially. More importantly, when the same compound was administered to mouse models of Parkinson’s disease, the animals showed measurable improvements in motor function and preserved significantly more dopaminergic neurons in the substantia nigra, the brain region most affected by the disease.

The implications of this work extend well beyond Parkinson’s disease. The ubiquitin-proteasome system is implicated in a wide range of neurodegenerative conditions, including Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. In each of these disorders, different proteins accumulate inside or outside neurons, but the underlying failure of protein disposal may share common mechanisms. If SUMOylation of the proteasome proves to be a general bottleneck in these conditions, then targeting it pharmacologically could offer a therapeutic strategy that cuts across multiple diseases.

Dr. Majd and her colleagues are careful to note that their findings, while promising, represent early-stage research. The mouse models used in the study do not fully replicate the complexity of human Parkinson’s disease, which typically develops over decades and involves multiple brain regions and cell types. Furthermore, the SUMOylation pathway is involved in many cellular processes beyond proteasome regulation, meaning that any drug targeting it would need to be carefully designed to avoid disrupting other essential functions. The team is now working to develop more selective inhibitors that can cross the blood-brain barrier and reach the relevant neurons without causing widespread side effects.

Independent experts in the field have responded with cautious optimism. Professor Maria Grazia Spillantini of the University of Cambridge, who was not involved in the study but has long studied alpha-synuclein aggregation, noted that the work adds an important piece to the puzzle of why specific neurons are vulnerable in Parkinson’s disease. She emphasized, however, that translating findings from cell cultures and mouse models into effective human therapies remains one of the greatest challenges in neurodegeneration research, a challenge that has defeated many promising approaches over the past two decades.

The Copenhagen team is already planning the next phase of their research, which will involve testing their lead compound in larger animal models and exploring whether biomarkers of proteasome dysfunction can be detected in cerebrospinal fluid or through brain imaging. Such biomarkers would be invaluable for identifying patients who might benefit from treatment before significant neuronal loss has occurred, a critical consideration given that by the time motor symptoms of Parkinson’s disease appear, a majority of dopaminergic neurons have already been lost.

For the millions of people worldwide living with Parkinson’s disease, and for the families who watch loved ones gradually lose their mobility and independence, this research offers something that has been in short supply: a genuinely new target. Current treatments, such as levodopa and deep brain stimulation, manage symptoms but do nothing to slow the underlying neurodegeneration. If the proteasome’s SUMOylation truly represents a druggable bottleneck in the disease process, then the work from Copenhagen may have opened a door that researchers have been searching for since alpha-synuclein was first linked to Parkinson’s disease nearly thirty years ago. Clinical trials remain years away, but the conceptual shift, from viewing protein accumulation as the problem to viewing failed protein disposal as the root cause, may prove to be the study’s most enduring contribution.

Subject of Research: Proteasome dysfunction and SUMOylation in Parkinson's disease neurodegeneration

Article Title: Retraction: METTL3 regulates ossification of the posterior longitudinal ligament via the lncRNA XIST/mir-302a-3p/USP8 axis

Article References: Frontiers Editorial Office (2026). Retraction: METTL3 regulates ossification of the posterior longitudinal ligament via the lncRNA XIST/mir-302a-3p/USP8 axis. Frontiers in Cell and Developmental Biology, 14, Article 2026364. https://doi.org/10.3389/fcell.2026.2026364

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.2026364

Keywords: Parkinson's disease, alpha-synuclein, proteasome, SUMOylation, neurodegeneration, dopaminergic neurons, ubiquitin-proteasome pathway, Lewy bodies, protein clearance, mitochondrial dysfunction, drug discovery, substantia nigra

The research was made possible by a uniquely rich resource. The donors were participants in InveCe.Ab, a population-based longitudinal study running in the town of Abbiategrasso since 2010, in which elderly volunteers underwent repeated neuromotor and neurocognitive assessments covering global cognition as well as memory, attention, executive functions, language and visuospatial abilities. When donors died, their brains were harvested within twenty-four hours and processed according to the Abbiategrasso Brain Bank protocol, which requires a complete histological characterization of all the main proteinopathies and vascular scoring before a neuropathological diagnosis is made. From this cohort, the researchers selected six subjects with a neuropathological diagnosis of Alzheimer’s disease, six with dementia with Lewy bodies, and three non-demented controls. This design matters because most post-mortem studies rely on diagnoses made from clinical records alone; here, the pathology was verified tissue by tissue.

The team dissected five brain regions from each subject: the hippocampus, the temporal cortex, the parietal cortex, the cingulate gyrus and the substantia nigra. These areas were chosen to capture the spatial heterogeneity of both diseases. RNA was extracted from cryopreserved tissue and libraries were prepared for RNA sequencing on an Illumina platform, with the resulting reads aligned to the human reference genome and quantified using the STAR/RSEM pipeline. Differentially expressed genes were identified with DESeq2, using a log2 fold-change threshold of at least one and a false discovery rate of 0.1 or less, a cutoff the authors justify for complex, heterogeneous primary brain tissue where a stricter threshold would generate excessive false negatives. Quantitative PCR served as a technical validation of the sequencing results.

The first major finding is a difference in scale. Alzheimer’s disease scrambles gene expression far more extensively than Lewy body dementia. In the Alzheimer’s brains, the temporal cortex alone yielded 1,571 differentially expressed genes, followed by the cingulate gyrus with 1,210, the hippocampus with 206, the parietal cortex with 109 and the substantia nigra with just 60. The Lewy body brains told an almost inverted story: the heaviest deregulation appeared in the substantia nigra with 138 differentially expressed genes, followed by the parietal cortex with 96, the hippocampus with 24, the cingulate gyrus with 13 and the temporal cortex with a mere 7. In both diseases the vast majority of affected transcripts were protein-coding messenger RNAs rather than long non-coding RNAs. The authors interpret this as evidence that Alzheimer’s pathogenesis is more complex and heterogeneous, whereas Lewy body disease follows a more stereotyped topography, a conclusion consistent with the neuropathological literature.

The biological character of the deregulated genes also followed a region-specific logic. In the Alzheimer’s brains, the hippocampus and temporal cortex showed transcriptomic changes dominated by synaptic function: enrichment analysis flagged synaptic transmission, ion channel activity, and the regulation of glutamatergic and GABAergic synapses, with many genes involved in voltage-gated potassium and sodium- and calcium-activated potassium channels strongly downregulated. By contrast, the cingulate gyrus and substantia nigra of the same brains were characterized by disruptions of proteostasis, the cellular machinery of protein folding and chaperone activity. In the Lewy body brains, the deregulated genes concentrated in the substantia nigra and parietal cortex pointed instead to a triad of failing processes: loss of proteostasis, an inadequate response to oxidative stress, and inflammation. The parietal cortex results also implicated the glial environment, a clue the authors consider potentially pivotal, since a parietal region affected later in the disease may mirror an early glial impairment in the substantia nigra that then snowballs into oxidative damage and protein mismanagement.

Some individual genes stood out. In the substantia nigra of Alzheimer’s subjects, the most heavily downregulated genes were HBA2 and HBB, which encode the alpha and beta chains of hemoglobin, hinting at vascular involvement. In the Lewy body brains, the shared functional enrichment between parietal cortex and substantia nigra converged on a single gene, HIF3A, which encodes the alpha subunit of Hypoxia-Inducible Factor 3 and is normally upregulated in response to low oxygen in the brain. Its upregulation and methylation have previously been associated with circadian rhythm disruption in Alzheimer’s disease; this study now links HIF3A to Lewy body disease as well, connecting hypoxia signaling, vascular function and neurodegeneration in a single thread.

When the researchers overlapped the gene lists from the two diseases region by region, a common molecular architecture surfaced. Every one of the five regions showed shared deregulation between the pathologies, with the parietal cortex showing the most overlap at 20 shared differentially expressed genes, followed by the substantia nigra with 17, the hippocampus with 6, and the temporal and cingulate cortices with 3 each. Several of these shared genes appeared in both diseases with the same direction of change. IGF2, which encodes insulin-like growth factor 2, a promoter of memory enhancement and neurogenesis in the adult brain, was upregulated in the hippocampus and temporal cortex of both groups, suggesting a compensatory, neuroprotective response. DNAJB1, a member of the heat shock protein family central to proteostasis, was downregulated in both diseases in the temporal cortex and cingulate gyrus, pointing to a shared collapse of protein quality control. In the hippocampus, the upregulated shared genes included CXCR4, a chemokine receptor signaling an exacerbated inflammatory state, and PTRF, a factor associated with caveolae and rRNA transcription. In the substantia nigra, the shared genes enriched for nitric oxide and carbon dioxide transport in relation to the vascular environment, alongside protein folding, reinforcing the idea that vascular and cell-to-cell communication pathways are compromised in both conditions.

The authors place these findings within the framework of the hallmarks of aging. Loss of proteostasis, chronic inflammation, impaired intercellular communication and mitochondrial and vascular dysfunction are all recognized drivers of aging, and each appeared in the shared molecular signature of the two dementias. From this perspective, the differentially expressed genes act as proxies of a nonphysiological aging trajectory that tips the brain from healthy aging into neurodegeneration. The brain attempts to cope, mounting compensatory responses such as IGF2 upregulation, but the balance ultimately fails. Because the shared signature spans the entire brain rather than a single lesion site, the researchers propose that neurodegenerative aging may be characterized by a whole-brain contest between pathological and compensatory mechanisms, with each disease emerging when that balance breaks down in a particular way.

The study has honest limitations, which the authors lay out in detail. The cohort is small, particularly the three controls, so all results should be read as preliminary. Post-mortem interval, agonal state, end-of-life conditions and dementia itself can all degrade RNA quality, and comorbidities such as diabetes, hypertension and limbic-predominant age-related TDP-43 encephalopathy may have influenced the expression profiles. Bulk RNA sequencing also cannot distinguish altered regulation within individual cell types from shifts in cellular composition, so the team could not attribute the signatures to specific cell populations, although comparisons with single-cell studies suggest oligodendrocytes and GABAergic inhibitory neurons are likely contributors. Even so, the work fills a gap, since single-cell atlases typically cover only one brain region. The therapeutic implication is perhaps the boldest claim: rather than continuing to chase immunological removal of amyloid or synuclein deposits after they have formed, the authors argue that understanding the molecular processes that occur before pathological lesions are deposited could enable personalized, preventive interventions aimed at restoring proteostasis and glial health, targeting the primary hallmarks of aging that appear to light the fuse for both diseases.

Subject of Research: Comparative whole-transcriptome mapping of molecular changes shared by Alzheimer's disease and dementia with Lewy bodies across five human brain regions

Article Title: A pattern to rule them all: tracing a human brain map of molecular aspects shared by Alzheimer’s disease and dementia with Lewy bodies

Article References: Ferrari, R. R., Garofalo, M., Di Gerlando, R., Pellegrini, E., Dragoni, F., Rizzo, B., Rossi, M., Calatozzolo, C., Guaita, A., Davin, A., Gagliardi, S., & Poloni, T. E. (2026). A pattern to rule them all: tracing a human brain map of molecular aspects shared by Alzheimer’s disease and dementia with Lewy bodies. GeroScience. https://doi.org/10.1007/s11357-026-02581-5

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02581-5

Keywords: Alzheimer's disease, dementia with Lewy bodies, transcriptomics, neurodegeneration, aging, proteostasis, substantia nigra, hippocampus, inflammation, RNA sequencing, alpha-synuclein, personalized therapy

The glymphatic system takes its name from the glial cells that support it, and it was first described as a brain-wide network of perivascular channels along which cerebrospinal fluid flows into brain tissue and interstitial fluid flows out. During sleep, these channels widen and clearance ramps up, carrying away amyloid-beta, tau, and other waste products. In Parkinson’s disease, the pathological hallmark is the accumulation of misfolded alpha-synuclein protein inside neurons, and scientists have long suspected that a failing glymphatic system could allow this protein to accumulate and spread faster, accelerating the disease process. What the new study adds is a direct clinical link: patients whose glymphatic clearance appears most impaired are precisely the ones whose drooling is worst.

To probe that connection, the team enrolled 72 people with Parkinson’s disease, split evenly into 36 patients who experienced drooling and 36 who did not, alongside 38 age-matched healthy controls. Every participant underwent magnetic resonance imaging and a battery of standardized clinical assessments covering disease severity, cognition, mood, and, for the patients with drooling, the severity and frequency of their symptoms using dedicated Parkinson’s-specific scales such as the Sialorrhea Clinical Scale for Parkinson’s disease and the Drooling Severity and Frequency Scale. The design allowed the researchers to compare three groups head to head and to ask which imaging features best separated droolers from non-droolers.

The centerpiece of the imaging analysis was a technique called diffusion tensor image analysis along the perivascular space, abbreviated DTI-ALPS. Diffusion tensor imaging tracks how water molecules diffuse through tissue, and because water moves more freely along the perivascular channels of the glymphatic system than across them, the ALPS index serves as a proxy for how efficiently fluid travels along those clearance routes. A lower ALPS index implies more restricted diffusion along the perivascular spaces, and by inference, more sluggish glymphatic function. The method has been applied in studies of Alzheimer’s disease, normal aging, and sleep disorders, but its use to stratify symptoms within Parkinson’s disease is still relatively novel.

The results were striking. Patients with drooling showed significantly lower ALPS indices on both the left and right hemispheres, as well as a lower bilateral average, than patients without drooling and than the healthy controls. The differences between the drooling and non-drooling Parkinson’s groups reached statistical significance on all three measures, with p values of 0.032 for the left index and 0.004 for both the right index and the bilateral average, while the gap between the drooling group and the healthy controls was even wider, with p values below 0.001 across the board. In other words, among people at the same stage of the same disease, those with drooling carried a distinct and measurable signature of impaired brain fluid dynamics.

The team also examined two other markers of glymphatic health. They measured the volume of the choroid plexus, the vascular tissue in the brain ventricles that produces cerebrospinal fluid, normalized to total intracranial volume. Both Parkinson’s groups, with and without drooling, showed significantly larger choroid plexus volumes relative to healthy controls, with p values of 0.001 and 0.006 respectively, suggesting that choroid plexus enlargement marks the disease itself rather than the drooling symptom specifically. Enlarged perivascular spaces, visible on MRI as dilated fluid-filled channels and another candidate readout of glymphatic drainage, showed no significant differences among the three groups, indicating that this particular structural marker was not sensitive to drooling status in this cohort.

Correlation analyses sharpened the story further. Across the patients, lower ALPS indices were associated with greater overall disease severity and, critically, with more severe drooling symptoms. The researchers then turned to receiver operating characteristic analysis, a standard statistical tool for testing how well a measurement discriminates between two groups, and found that the bilateral average ALPS index was the best single separator of Parkinson’s patients with drooling from those without, achieving an area under the curve of 0.725. A final multivariate logistic regression, which adjusted for other clinical variables, confirmed that the bilateral ALPS index stood as an independent predictor of drooling, with an odds ratio of 0.063 and a 95 percent confidence interval of 0.004 to 0.938 and a p value of 0.045. Because the odds ratio falls below one, it indicates that higher, healthier glymphatic function is associated with lower odds of drooling.

What might connect a brain-wide clearance system to saliva pooling at the corner of the mouth? The authors point to alpha-synuclein. Pathological alpha-synuclein in Parkinson’s disease is not confined to the substantia nigra; it spreads through brainstem and autonomic circuits, including regions that govern swallowing and salivary control. If glymphatic dysfunction permits pathological protein to accumulate more readily in those circuits, the autonomic and motor regulation of swallowing could falter, allowing saliva to collect and spill. The choroid plexus enlargement observed in both patient groups adds a second thread, since the choroid plexus is the source of the cerebrospinal fluid that drives glymphatic flow, and inflammatory or age-related changes in this tissue could compromise the driving pressure of the whole clearance network. The researchers caution that their findings provide indirect, in vivo evidence of this mechanism rather than a direct demonstration, but the concordance between the imaging signal and the clinical symptom is difficult to dismiss.

The practical implications are considerable. Drooling affects a large share of Parkinson’s patients, causing skin irritation around the mouth, increased risk of aspiration and chest infections, and profound embarrassment that leads many people to withdraw from social life. Current treatments, from anticholinergic drugs to botulinum toxin injections into the salivary glands, target the downstream output rather than any upstream neurological cause. If the ALPS index can be validated in larger and more diverse cohorts, it could function as an imaging biomarker that flags patients at risk of developing or worsening drooling, allowing earlier intervention and giving trial designers an objective measure for testing therapies aimed at restoring glymphatic function. The authors suggest that the index may prove useful for predicting both the occurrence and the progression of the symptom over time.

The study has limits that the team acknowledges. With 72 patients drawn from a single center, the cohort is modest, and the cross-sectional design captures a snapshot rather than the arc of disease, so it cannot yet prove that glymphatic decline precedes drooling rather than accompanying it. The ALPS index itself remains an indirect measure, and its interpretation can be influenced by head position, imaging parameters, and age. Even so, the convergence of evidence, from group differences and symptom correlations to independent predictive value in regression, makes a compelling case that the brain’s drainage system matters for one of Parkinson’s most underappreciated symptoms. As glymphatic research moves from animal models toward the clinic, this study signals that waste clearance may hold explanatory power well beyond neurodegeneration itself, reaching into the everyday, embodied symptoms that shape patients’ lives.

Subject of Research: Glymphatic system dysfunction and drooling severity in Parkinson's disease

Article Title: Glymphatic dysfunction predicts drooling severity in Parkinson’s disease

Article References: Huang, T., Tian, Y., Xia, Y., Yao, J., Gao, Q., Shang, S., Deng, T., Muthaiah, V. P., Zhang, Y., Yin, X., & Chen, Y. (2026). Glymphatic dysfunction predicts drooling severity in Parkinson’s disease. BMC Medicine. https://doi.org/10.1186/s12916-026-05299-5

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05299-5

Keywords: Parkinson's disease, glymphatic system, drooling, sialorrhea, DTI-ALPS, MRI biomarker, alpha-synuclein, choroid plexus, perivascular spaces, neurodegeneration, non-motor symptoms, brain clearance

The core problem the researchers identify is heterogeneity. Two people diagnosed with Parkinson’s disease on the same day can follow radically different trajectories: one may retain sharp cognition for decades while motor symptoms slowly worsen, whereas another may face rapid cognitive decline within a few years. The perspective attributes this variability to differences in underlying molecular pathways, cellular vulnerabilities, network-level dysfunction, and compensatory mechanisms. Existing staging systems, including the Neuronal Alpha-Synuclein Disease Integrated Staging System and the SynNeurGe research diagnostic criteria, were designed to diagnose and stage the disease but do not fully capture how individual patients differ from one another.

The proposed framework organizes this diversity along six complementary biological axes. The first is the dominant pathological process, meaning the primary molecular and cellular mechanisms driving neurodegeneration in a given patient. The second is the spatial distribution of pathology, describing whether damage concentrates in the brainstem and deep gray nuclei, spreads preferentially through limbic structures, or reaches the neocortex early. The third is propagation architecture, the spatiotemporal trajectory through which pathology appears to travel, including the distinction between brain-first and body-first disease. The fourth is the temporal dynamics of progression, which separates slow from fast progressors and linear from punctuated decline. The fifth is co-pathology burden, the coexistence of Alzheimer-type amyloid and tau pathology, TDP-43 inclusions, and cerebrovascular disease alongside alpha-synuclein. The sixth is system response and resilience, the brain’s capacity to buffer the clinical impact of accumulating damage.

Each dimension can be interrogated with specific MRI techniques, and the authors map these tools explicitly. Quantitative susceptibility mapping quantifies iron accumulation in the substantia nigra, putamen, and dentate nucleus, and a technique called susceptibility source separation can isolate the paramagnetic iron signal to document progressive nigral iron spread. Neuromelanin-sensitive MRI measures pigment-containing neuron integrity in the substantia nigra pars compacta and the locus coeruleus, with regional neuromelanin loss correlating with motor and cognitive severity. Diffusion tensor imaging yields fractional anisotropy and diffusivity measures that index white matter integrity, while T1-weighted volumetry and deformation-based morphometry localize patterns of regional atrophy.

Spatial subtypes emerge clearly from data-driven clustering of these imaging features. The perspective describes brainstem-predominant patterns with early substantia nigra and locus coeruleus involvement, limbic-predominant patterns beginning in the amygdala and temporal cortex, neocortical or cortex-first patterns with early frontal and parietal thinning, and a diffuse-malignant pattern marked by accelerated multi-regional atrophy and worse longitudinal decline in motor function, cognition, and daily living activities. A restricted deep-gray-matter-first pattern shows early nigrostriatal involvement with relative cortical sparing and milder early cortical symptoms. Hemispheric asymmetry in neuromelanin loss and iron deposition contralateral to the side of motor onset has also been documented, reflecting asymmetric nigral involvement.

Propagation architecture is perhaps the most conceptually ambitious dimension. The authors review connectivity-informed epicenter models that combine structural connectivity with regional atrophy to infer where degeneration begins and how it spreads, with cerebellar and midbrain epicenters linked to faster motor progression and cortical or striatal epicenters to milder courses. They also discuss disease reservoir models, in which cortical thinning propagates from a reservoir through regions with strong functional connectivity, and epidemic-style models based on Susceptible-Infected-Removed mathematics that predict spatial and temporal atrophy patterns seeded from the substantia nigra. The authors caution that MRI provides only indirect insights into propagation and cannot independently verify where the pathology originated, so imaging must be interpreted alongside autonomic testing, longitudinal clinical observation, and alpha-synuclein amplification assays.

Temporal dynamics and co-pathology burden round out the picture. Longitudinal neuromelanin MRI and serial quantitative susceptibility mapping can track progressive neuromelanin loss and iron accumulation over time, while repeated volumetry quantifies rates of regional atrophy. Trajectory modeling approaches such as mixed-effects models and latent class growth analyses can distinguish linear from non-linear progression and identify inflection points where decline accelerates. On the co-pathology side, white matter hyperintensities and microbleeds reflect cerebrovascular burden, medial temporal atrophy may suggest concomitant Alzheimer’s pathology, and inferior temporal thinning has been associated with probable REM sleep behavior disorder and higher risk of cognitive impairment. The authors stress that these MRI markers are approximations that require validation with tau and amyloid PET, cerebrospinal fluid biomarkers, and genetic profiling.

The resilience dimension is the most difficult to measure directly, because compensatory mechanisms such as cognitive reserve, synaptic plasticity, and glial support are not visible to any scanner. Instead, the framework relies on imaging-clinical dissociation: patients who maintain function despite substantial atrophy occupy the high-resilience end of the spectrum, while those with severe symptoms despite minimal pathological burden sit at the low end. Resting-state functional MRI can reveal compensatory network reorganization, and cortical thickness in frontal and parietal association cortices is linked to cognitive reserve. The authors argue that resilience-based stratification may be particularly valuable in prodromal patients, where enhancing compensatory capacity before substantial pathology accumulates could delay or prevent clinical onset.

Critically, the authors emphasize that the six dimensions are continuous biological axes rather than discrete categories, and that familiar labels such as cortex-first, body-first, or brain-first should be treated as estimates of recurring patterns rather than distinct disease entities. Each patient occupies a unique position along every axis, generating a multidimensional profile that could be visualized as a radar plot. This framing explains why patients sharing the same diagnosis can experience such different trajectories, and it offers a mechanistic foundation for precision medicine approaches that current diagnostic and staging systems cannot provide.

Turning this vision into clinical practice will require a demanding translational roadmap. The authors call for standardized operational definitions of each dimension, harmonized multimodal datasets spanning imaging, clinical, genetic, and molecular biomarkers, and models that prioritize interpretability over raw predictive performance. Independent multicenter validation must demonstrate stability across imaging platforms and acquisition protocols, and prospective studies must show that stratification genuinely improves prognostic accuracy or patient selection for disease-modifying therapies. Regulatory engagement, ethical safeguards around equitable access and algorithmic transparency, and integration of MRI with fluid, molecular, and PET measures all feature in their roadmap. MRI, the authors conclude, should be viewed as one layer within a broader multimodal framework, but its scalability and accessibility make it the natural foundation for transforming Parkinson’s disease care from a one-size-fits-all approach into truly personalized medicine.

Subject of Research: A multidimensional MRI-based framework for characterizing biological heterogeneity and patient stratification in Parkinson's disease

Article Title: Biological heterogeneity in Parkinson’s disease: implications for MRI-based patient stratification

Article References: Pokotylo, M. M., Brüggemann, N., & Prasuhn, J. (2026). Biological heterogeneity in Parkinson’s disease: implications for MRI-based patient stratification. npj Parkinson's Disease, 12(1), Article 207. https://doi.org/10.1038/s41531-026-01544-z

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01544-z

Keywords: Parkinson's disease, MRI, biological heterogeneity, patient stratification, neuromelanin-sensitive MRI, quantitative susceptibility mapping, diffusion tensor imaging, alpha-synuclein, co-pathology, brain resilience, precision medicine, npj Parkinson's Disease

The team’s starting point was a simple epidemiological observation with profound implications. Mining a published microarray dataset of 41 human frontal cortex samples spanning ages 24 to 106, they found that CHCHD2 gene expression declines steadily and significantly across the human lifespan, with a Pearson correlation coefficient of −0.63. The drop was present in both sexes but was steeper and statistically stronger in women. Because CHCHD2 levels were already known to be reduced in the brains and even the red blood cells of Parkinson’s patients, the finding suggested that the gradual erosion of this mitochondrial protein could be one of the quiet preconditions that makes an aging brain vulnerable to Lewy body pathology in the first place.

To test whether boosting CHCHD2 could counteract aging, the researchers engineered transgenic mice expressing the human wild-type protein specifically in neurons, using the same prion protein promoter strategy they had previously used to create mice carrying the Parkinson’s-linked T61I mutation. The resulting CHCHD2-WT animals expressed roughly 2.3-fold more CHCHD2 transcript than normal littermates, and the extra protein correctly localized to the mitochondrial intermembrane space, the compartment where the endogenous protein resides. Crucially, the mice appeared entirely normal: their body weights, brain morphology, synaptic protein levels, and hippocampal electrophysiology, including long-term potentiation at the CA3-CA1 synapse, were indistinguishable from wild-type controls. Whatever the extra CHCHD2 was doing, it was not disturbing normal neuronal function.

The protective effects emerged only with age, and they were striking. At 12 months of age, the CHCHD2-WT mice had significantly more tyrosine hydroxylase-positive dopaminergic neurons in the substantia nigra than wild-type littermates, the very cell population that dies in Parkinson’s disease. By 18 months, when ordinary mice show mounting neuroinflammation, the transgenic animals displayed markedly reduced immunoreactivity for Iba1 and GFAP, the standard markers of activated microglia and astrocytes. Silver staining of the substantia nigra revealed nearly twice as many degenerating axons in age-matched mice carrying the T61I mutation compared with both wild-type and CHCHD2-WT animals, and the mutant mice also accumulated conspicuous CHCHD2-positive aggregates in the midbrain that were absent from the protected animals.

Proteomics told a similar story at the level of the entire protein complement of the cortex. In 12-month-old CHCHD2-WT mice, unbiased mass spectrometry of soluble and insoluble cortical fractions showed that the vast majority of altered proteins shifted in the direction of solubility: 169 of 240 significantly changed soluble proteins were elevated, while most of the 145 altered insoluble proteins were reduced. A contingency analysis confirmed that the ratio of insoluble to soluble proteins fell significantly, with an odds ratio of 0.381. That stands in dramatic contrast to the T61I mutant brains, which the same group had previously shown to skew in the opposite direction with an odds ratio of 23.4. In other words, wild-type CHCHD2 keeps the proteome fluid and degradable, while the mutant pushes it toward the aggregated, detergent-resistant state that defines proteinopathies.

The mechanistic heart of the paper lies in what happened when the researchers compared the two variants head to head. Pathway analysis of the cortical proteome revealed that the T61I mutation broadly suppresses the CLEAR signaling network, the transcriptional program that coordinates lysosomal biogenesis and function, alongside disruptions of mTOR and integrated stress response pathways. Lysosomal hydrolases, including cathepsin B, cathepsin L, and hexosaminidase A, were markedly depleted in mutant brains. Using a proximity-labeling interactome screen in which CHCHD2 variants were targeted to the mitochondrial intermembrane space fused to the BirA biotin ligase, the team discovered that T61I preferentially associates with cathepsins B and L. Proximity ligation assays and co-immunoprecipitation confirmed the interaction, and fluorometric enzyme assays showed that cathepsin B and L activities were significantly reduced in the forebrains of mutant mice, while cathepsin D was untouched.

Why does this matter for Parkinson’s disease? Cathepsin B and cathepsin L are the principal lysosomal enzymes that cleave alpha-synuclein within its amyloid-forming region, and genetic evidence links cathepsin B levels to Parkinson’s risk. When the researchers exposed cultured hippocampal neurons to sonicated alpha-synuclein pre-formed fibrils, cells expressing wild-type CHCHD2 cleared the pathological protein efficiently over 45 hours, whereas T61I-expressing cells retained significantly more of it. The mutant protein also accumulated in an insoluble form within isolated lysosomal fractions from mouse cortex, permeabilized lysosomal membranes as measured by galectin-3 puncta, and induced a greater than fourfold increase in swollen LAMP1-positive vacuoles. Recombinant T61I protein, unlike the wild-type protein, aggregated spontaneously at body temperature and resisted degradation after uptake into cells, suggesting that the misfolded mutant physically clogs and damages the very disposal machinery it is supposed to support.

Transmission electron microscopy provided the visual proof of the mitochondria-lysosome axis in action. In young wild-type mice, more than 86 percent of cortical mitochondria were classified as healthy, with elongated shapes and dense cristae, and every lysosome fell into the healthiest category. By 12 to 13 months of age, ordinary mice showed the expected deterioration: rounded mitochondria with sparse cristae and lysosomes stuffed with lipofuscin and lipid droplets. The CHCHD2-WT mice retained significantly healthier organelles on both counts, while the T61I animals fared worst of all, with no lysosomes classified as healthy and mitochondria showing severe ultrastructural abnormalities. The findings align with the human data: in postmortem frontal cortex from nine cortical Lewy body disease patients, soluble CHCHD2 was reduced by about 65 percent and cathepsin B by about 45 percent relative to controls, with the two proteins correlating significantly across all samples.

What emerges is a coherent model of how the aging brain loses its grip on protein quality control. CHCHD2, a mitochondrial intermembrane space protein, appears to sustain lysosomal health, possibly through the vesicular trafficking routes that shuttle material from mitochondria to lysosomes, and the T61I mutation corrupts this relationship by misfolding, aggregating, sequestering cathepsins, and rupturing lysosomal membranes. The authors are careful to note that the causal direction between mitochondrial and lysosomal abnormalities remains to be fully established, and the precise basis for the selectivity toward cathepsins B and L is still unclear. But the therapeutic implication is hard to miss: strategies that stabilize CHCHD2 expression, prevent its misfolding, or block the pathological interaction between mutant CHCHD2 and lysosomal cathepsins could simultaneously protect both organelles, addressing a root cause of the proteostatic failure that underlies Parkinson’s disease and perhaps brain aging more broadly. Preventing the age-associated decline of a single small mitochondrial protein, the study suggests, may be one of the most economical ways to keep an aging brain clean, functional, and resilient.

Subject of Research: Role of CHCHD2 in maintaining mitochondria-lysosome homeostasis during brain aging and Lewy body disease

Article Title: CHCHD2 mitigates age-associated proteostatic collapse by maintaining homeostasis of the mitochondria-lysosome axis

Article References: Kee, T. R., Masters, B. M., Tran, K. D., Jeon, H., Long, M., Xu, G., Khan, S. A., Vázquez-Rosa, E., Sridharan, P. S., Koh, Y., Fujioka, H., Chaput, D., Wang, X., Zhao, X., Pieper, A. A., Kang, D. E., & Woo, J.-A. A. (2026). CHCHD2 mitigates age-associated proteostatic collapse by maintaining homeostasis of the mitochondria-lysosome axis. Acta Neuropathologica, 152(1), Article 54. https://doi.org/10.1007/s00401-026-03093-4

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03093-4

Keywords: CHCHD2, Parkinson's disease, Lewy body disorders, mitochondria-lysosome axis, lysosomes, cathepsin B, cathepsin L, alpha-synuclein, proteostasis, neurodegeneration, brain aging, neuroinflammation

The study, published in Biomedical Microdevices, describes a multiplexed aptasensor built on a humble cellulose substrate. Led by Jagriti Narang, with Saumitra Singh, Anam Ayaz, Osheen Ansari, and Humaira Farooqi as co-authors, the team inscribed carbon and silver electrodes directly onto paper using screen-printing techniques, creating a flexible, lightweight sensing platform that requires no expensive laboratory infrastructure to manufacture. The device features two independently functionalized working electrodes, each dedicated to a different disease biomarker, allowing a single measurement session to interrogate both Alzheimer’s-associated and Parkinson’s-associated proteins at once.

The two targets at the heart of the sensor are amyloid beta-42, the peptide fragment notorious for aggregating into the plaques that define Alzheimer’s disease, and alpha synuclein-60, a protein species linked to the Lewy body pathology characteristic of Parkinson’s disease. Both molecules circulate at vanishingly low concentrations in biological fluids, which is precisely why conventional diagnostic approaches struggle. Detecting them reliably demands a sensing interface that can amplify vanishingly small molecular events into measurable signals—something the Indian team achieved through a clever combination of nanomaterials and biological recognition elements.

The amplification strategy centers on zinc oxide nanorods, which the researchers grew onto the carbon working electrodes to dramatically increase the effective surface area available for biomolecule immobilization. Zinc oxide is a favorite material in biosensor engineering for good reason: it is biocompatible, electrically conductive, and its high isoelectric point makes it an excellent scaffold for anchoring proteins and nucleic acids. By decorating the nanorod-covered electrodes with target-specific DNA aptamers—short, synthetic single-stranded DNA sequences that fold into precise three-dimensional shapes capable of binding a single molecular target with antibody-like specificity—the team created two distinct biorecognition surfaces on one chip.

The readout method is electrochemical impedance spectroscopy, a label-free technique that measures how much a surface resists the transfer of electrons in solution. In the sensor’s baseline state, a small redox probe can shuttle freely between the electrode and the surrounding electrolyte. When the target protein—amyloid beta-42 on one electrode, alpha synuclein-60 on the other—binds to its aptamer, the bulky protein layer physically blocks that electron transfer, increasing what electrochemists call the charge-transfer resistance. The magnitude of that increase scales with the concentration of the target, so a simple impedance measurement translates directly into a quantitative biomarker reading, with no chemical labels, enzymes, or secondary reagents required.

The performance figures are striking for a paper-based platform. The sensor exhibited a linear response spanning five orders of magnitude, from 0.1 nanograms per milliliter up to 10 micrograms per milliliter, for both biomarkers. The limits of detection came out at 4.41 nanograms per milliliter for amyloid beta-42 and 2.62 nanograms per milliliter for alpha synuclein-60—concentrations low enough to be relevant for physiological monitoring. Equally important, the team demonstrated that the device retains its responsiveness in artificial cerebrospinal fluid and artificial saliva, two physiologically mimicked matrices that are far messier than a clean buffer solution. Saliva, in particular, is an attractive sample type for decentralized testing because it can be collected non-invasively by patients themselves, without needles or clinical staff.

Multiplexing is the quiet innovation here. Most existing biosensors detect a single biomarker, but neurodegenerative diseases do not present as single-molecule problems. Alzheimer’s and Parkinson’s share overlapping symptoms, overlapping pathologies, and in many patients overlapping diagnoses, and clinicians increasingly recognize that distinguishing between them—or catching both—requires looking at multiple molecular indicators in parallel. By building two independently addressable working electrodes onto one paper strip, the researchers created a platform where a single drop of sample could, in principle, yield a two-disease molecular profile simultaneously, at a fraction of the cost of running separate assays.

The broader context makes the work timely. Paper-based microfluidics and screen-printed electrodes have surged in popularity over the past decade because they promise something the diagnostics industry has long struggled to deliver: laboratory-quality molecular testing at a price point and form factor suitable for clinics in resource-limited settings, pharmacies, and eventually the home. The COVID-19 pandemic demonstrated both the demand for and the feasibility of rapid, disposable biosensing, and researchers worldwide have been racing to apply the same design philosophy to chronic diseases, where early detection could shift the entire trajectory of patient care. Electrochemical aptasensors, which pair the stability and synthetic ease of DNA with the sensitivity of electrochemical transduction, have emerged as one of the most promising routes.

The authors are candid about the distance between proof of concept and clinical deployment. Their abstract explicitly flags the hurdles that remain: the low concentrations of neurodegenerative biomarkers in real samples, interference from the complex protein mixtures in genuine biological fluids, nonspecific adsorption of off-target molecules onto the sensor surface, variability from sensor to sensor, and questions of long-term storage stability. The current results were obtained in artificial matrices rather than real patient samples, and the team acknowledges that optimization of surface immobilization chemistry, antifouling behavior, and sensitivity—followed by validation using real clinical saliva and cerebrospinal fluid—will be required before the platform can approach practical diagnostic use.

Those caveats are standard for early-stage biosensor research, and they do not diminish the significance of what has been demonstrated. What the Jamia Hamdard team has built is a complete architectural template: a disposable paper substrate, printed carbon and silver electrodes, nanostructured signal amplification, aptamer-based molecular recognition, and label-free impedance readout, all integrated into a multiplexed format targeting two of the most consequential proteins in neurodegeneration. If subsequent studies can carry that architecture through clinical validation, the vision of a cheap paper strip that screens for Alzheimer’s and Parkinson’s in a doctor’s office—or even at home—moves a meaningful step closer to reality, and the growing global burden of these diseases gains a potential new line of early defense.

Subject of Research: A multiplexed paper-based impedimetric aptasensor using zinc oxide nanorods for simultaneous detection of Alzheimer's and Parkinson's disease biomarkers

Article Title: Multiplexed impedimetric zinc oxide nanorods-modified aptasensor on carbon ink-inscribed paper electrodes for the specific and sensitive co-detection of Alzheimer’s and Parkinson’s disease

Article References: Singh, S., Ayaz, A., Ansari, O., Farooqi, H., & Narang, J. (2026). Multiplexed impedimetric zinc oxide nanorods-modified aptasensor on carbon ink-inscribed paper electrodes for the specific and sensitive co-detection of Alzheimer’s and Parkinson’s disease. Biomedical Microdevices, 28(4), Article 73. https://doi.org/10.1007/s10544-026-00855-5

Image Credits: AI Generated

DOI: 10.1007/s10544-026-00855-5

Keywords: Alzheimer's disease, Parkinson's disease, biosensor, aptasensor, zinc oxide nanorods, electrochemical impedance spectroscopy, amyloid beta-42, alpha synuclein, paper-based diagnostics, point-of-care testing, multiplexed sensing, neurodegenerative diseases

The significance of this work lies in the central mystery it helps to address. Parkinson’s disease affects more than ten million people worldwide and is characterised by two intertwined processes: the progressive death of dopamine-producing neurons in a region of the brain called the substantia nigra, and the build-up of abnormal clumps of alpha-synuclein inside nerve cells. These aggregates, known as Lewy bodies and Lewy neurites at later stages, are thought to contribute to neuronal dysfunction and death. For years, therapeutic strategies have sought ways to prevent the formation of these clumps or to clear them once they appear, but the tools of the brain’s own immune system have generally been viewed with ambivalence. Microglia, when persistently activated, are known to release inflammatory signals that can damage neurons, and much of the recent literature has cast them as accomplices in neurodegeneration rather than as protectors.

The Oxford team, led by first author Dr Hung-Ju Chueh and senior author Professor George Tofaris of the Nuffield Department of Clinical Neurosciences, approached the question with a human-specific experimental system. They derived induced pluripotent stem cells, which can be reprogrammed to become almost any cell type in the body, and used them to generate both dopamine-producing neurons and microglia in the laboratory. This allowed the two cell types to be studied together in a controlled environment that reflects human biology far more closely than animal models, in which alpha-synuclein aggregation and microglial behaviour can differ substantially from the human condition. The researchers then created conditions in which alpha-synuclein aggregates formed inside the neurons, either by increasing the dosage of the alpha-synuclein gene or by exposing the cells to pre-formed alpha-synuclein fibrils that act as molecular templates, coaxing the neurons’ own protein to misfold in the same characteristic way.

What the team observed when microglia encountered these aggregate-laden neurons was striking. The immune cells did not engulf and digest entire neurons, as might be expected in a conventional phagocytic response to damaged cells. Instead, they engaged in a process called trogocytosis, from the Greek word for gnaw, in which one cell nibbles small portions of material from the membrane or cytoplasm of another. In this case, the microglia selectively removed the portions of the neuron containing the aggregated alpha-synuclein, effectively extracting the pathological protein from within the living cell. Dr Chueh emphasised the precision of this response, noting that the microglia were not simply engulfing damaged neurons but instead removing parts of the neuron containing aggregated alpha-synuclein, which suggests that at certain stages of the disease microglia help neurons dispose of potentially harmful material.

This distinction matters enormously for how the immune system is understood in neurodegeneration. Trogocytosis has been described in other contexts, particularly in the immune system’s interactions with tumour cells and in certain developmental processes, but its role in clearing intracellular protein aggregates from neurons had not been demonstrated before. The mechanism offers a way for the brain to deal with a problem that ordinary protein degradation pathways inside the neuron apparently cannot solve on their own. Aggregated alpha-synuclein is notoriously resistant to the cell’s internal disposal machinery, including the proteasome and lysosome systems, and once seeds of misfolded protein take hold they can propagate from cell to cell, spreading pathology through connected brain circuits. A mechanism by which microglia can reach into neurons and remove these seeds while preserving neuronal structure and function represents a fundamentally different kind of intervention from simply killing and replacing damaged cells.

The research went further, dissecting the molecular signals that govern this protective behaviour. The team found that the response was fine-tuned by communication between the two cell types through specific receptors: P2RY12, a receptor involved in microglial sensing and surveillance, and CD22, an inhibitory receptor that restrains immune activation. In addition, the microglia operated under what the researchers describe as a self-regulated brake, mediated by the cytokine IL-10, an anti-inflammatory signalling molecule that the cells produce themselves. This internal braking system prevents the microglia from escalating into a full inflammatory response that would damage healthy tissue, ensuring that the nibbling remains targeted and proportionate. The interplay of sensing signals, inhibitory checkpoints and self-produced anti-inflammatory feedback suggests a carefully calibrated system rather than a crude immune reaction.

Using single-cell RNA sequencing, a technique that allows researchers to read the gene expression profiles of individual cells rather than averaging across a whole population, the team identified a distinct subpopulation of activated microglia associated with this beneficial clearance response. This is an important methodological advance, because bulk analyses of microglial gene expression in diseased brains have often lumped together cells performing very different functions, some harmful and some protective. Being able to distinguish a clearance-competent microglial state opens the possibility of identifying equivalent cells in human brain tissue and, ultimately, of finding ways to expand or enhance this population therapeutically. Professor Tofaris noted that the findings highlight that the immune response in Parkinson’s disease is more nuanced than simply being beneficial or harmful, and that understanding how to enhance and monitor such beneficial microglial functions without triggering damaging inflammation could open up new avenues for developing disease-modifying treatments.

A second major discovery concerns a protein called glycoprotein non-metastatic melanoma protein B, or GPNMB, which appears to be an essential component of the protective machinery. Genetic variation at the GPNMB locus had previously been linked to Parkinson’s disease risk through genome-wide association studies, large-scale genetic surveys that compare the DNA of patients and healthy controls, but the functional role of the protein in the disease had remained unclear. The Oxford researchers found that GPNMB was upregulated in microglia exposed to neurons containing alpha-synuclein aggregates, and that the protein interacted with the pathological alpha-synuclein inside the microglia after the material had been nibbled away from the neurons. Crucially, when the team selectively reduced GPNMB expression in microglia using CRISPR interference, a genetic technique that silences specific genes without cutting the DNA, the cells became markedly less effective at clearing the aggregates, providing direct evidence that GPNMB plays an active role in the process rather than being a passive byproduct.

The human relevance of the GPNMB finding was reinforced by evidence from brain tissue. The researchers examined post-mortem tissue from the substantia nigra, the brain region most affected in Parkinson’s disease, from individuals who had died with either incidental alpha-synuclein pathology, an asymptomatic stage in which the protein aggregates are present without clinical disease, or full Parkinson’s disease. In both cases, GPNMB was increased in the microglia of this vulnerable region. This pattern suggests that the protective response is not merely an artefact of the laboratory system but occurs in the human brain, and that it may be engaged even in the earliest pathological stages, before symptoms emerge. If so, the window during which enhancing microglial clearance could slow or prevent disease progression may be wider than previously assumed, and GPNMB levels could potentially serve as a marker of this protective activity.

The broader implications of the study extend across several fronts in Parkinson’s research. First, it provides a concrete mechanism by which the immune system can be protective in neurodegeneration, countering the prevailing narrative of microglia as primarily inflammatory villains and suggesting that blanket immunosuppression might inadvertently remove a beneficial defence. Second, it identifies molecular targets, including the P2RY12 and CD22 signalling pathways, the IL-10 brake and GPNMB itself, that could be manipulated pharmacologically to strengthen the clearance response. Third, it demonstrates the power of human stem cell co-culture systems combined with single-cell profiling to reveal biology that animal models have missed. Much work remains before these findings translate into treatments: the researchers and the field will need to determine how trogocytosis is triggered in the living brain, how it changes as disease advances, and whether enhancing it in patients is safe and effective. But for a disease in which available therapies manage symptoms without slowing the underlying neurodegeneration, the image of brain immune cells carefully nibbling toxic protein out of struggling neurons offers a genuinely new and hopeful direction for disease-modifying drug development.

Subject of Research: Microglial clearance of intraneuronal alpha-synuclein aggregates in Parkinson's disease

Article Title: Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

Article References: Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Parkinson's disease, microglia, alpha-synuclein, trogocytosis, GPNMB, neurodegeneration, dopamine neurons, iPSC models, single-cell RNA sequencing, IL-10, substantia nigra, neuroimmunology

The study, which combined single-nucleus RNA sequencing, spatial transcriptomics and spatial metabolomics in male mice carrying the human A53T alpha-synuclein mutation, represents one of the most comprehensive attempts yet to chart how Parkinson’s disease reshapes the brain’s immunometabolic landscape. Alpha-synuclein is the protein that clumps into the characteristic Lewy bodies of Parkinson’s, and understanding how this pathology propagates through brain tissue — cell by cell, region by region — has become one of the field’s central quests. The team supplemented the mouse work with an independent model using adeno-associated virus to overexpress alpha-synuclein, and crucially, with human midbrain and cerebrospinal fluid samples from patients, giving the findings a translational anchor that mouse studies alone often lack.

What the researchers found was a distinct disease-associated oligodendrocyte lineage, marked by elevated expression of two genes: Il33, which encodes the signaling molecule interleukin 33, and Kirrel3, a gene involved in synaptic and cellular adhesion. This population was not a fleeting artifact of one model or one disease stage. It expanded progressively as pathology accumulated in both the transgenic A53T mice and the viral overexpression model, suggesting that the emergence of these altered oligodendrocytes tracks closely with the burden of misfolded alpha-synuclein in the brain.

The significance of interleukin 33 lies in where it acts. The team found that the signaling molecule itself was upregulated in oligodendrocytes, while its receptor, known as ST2, was upregulated in microglia — the brain’s resident immune cells. This arrangement creates a communication channel between two cell types that are rarely cast as leading actors in Parkinson’s disease. Oligodendrocytes, stressed or transformed by the surrounding pathology, appear to send inflammatory signals through interleukin 33, and microglia, primed by elevated receptor expression, appear poised to receive them and respond.

To test whether this crosstalk actually matters for the disease process, the researchers performed bidirectional manipulation of the Il33 gene in oligodendrocytes — turning it up in some experiments and down in others. The results were striking. Altering oligodendrocyte interleukin 33 changed the activation state of microglial ST2 signaling, and it also changed two of the most consequential measures in Parkinson’s research: the burden of insoluble alpha-synuclein in the brain and the motor performance of the animals. In other words, a signal originating in the myelin-forming cells of the brain influenced both the molecular hallmark of the disease and the behavioral symptoms it produces.

Beyond the oligodendrocyte story, the spatial multi-omics approach revealed a second major theme: metabolic dysregulation. In the substantia nigra and the ventral tegmental area — the two midbrain regions that house the dopamine neurons most affected in Parkinson’s disease — the team found that transcriptomic and metabolomic changes converged on lipid-related and glutamate-related pathways. This convergence is notable because it links two processes that have each attracted attention in neurodegeneration research separately: disturbances in lipid metabolism, which have been increasingly implicated in alpha-synuclein aggregation, and glutamate signaling, the brain’s primary excitatory neurotransmitter system, whose excess can become toxic to neurons.

The spatial dimension of the study is what sets it apart technically. Traditional single-cell sequencing requires dissociating tissue, which strips away the geographic context that is often essential for understanding disease. By pairing single-nucleus RNA sequencing with spatial transcriptomics — which preserves the physical location of gene expression — and spatial metabolomics, which maps small metabolic molecules across tissue sections using mass spectrometry imaging, the researchers could see not just which cells were altered but where in the diseased brain those alterations clustered, and how the chemical environment of specific regions shifted with disease progression.

The human data provide perhaps the most clinically resonant finding. Both interleukin 33 and its receptor ST2 were elevated not only in mouse models but in human Parkinson’s disease midbrain tissue and in patients’ cerebrospinal fluid. That elevation in cerebrospinal fluid is particularly intriguing, because the fluid surrounding the brain and spinal cord can in principle be sampled in living patients through a lumbar puncture. If the mouse findings translate, proteins in this signaling axis could eventually serve as accessible biomarkers reflecting the state of a cellular pathway deep inside the brain.

The authors emphasize that their dataset constitutes a spatially resolved resource for the broader research community, cataloging how the immunometabolic landscape of the Parkinson’s brain changes across disease stages. Such resources matter because Parkinson’s drug development has been dominated for decades by dopamine-replacement strategies that treat symptoms without slowing the underlying neurodegeneration. If oligodendrocyte interleukin 33–ST2 signaling genuinely modulates alpha-synuclein burden and motor decline, it offers a new node at which disease modification might be attempted — one that targets the glial environment surrounding vulnerable neurons rather than the neurons themselves.

Important caveats remain. The mouse work was conducted exclusively in male animals, and sex differences are well documented in both Parkinson’s disease biology and immune signaling, so extending the findings to female models will be an essential next step. The published version is also an early-release, peer-reviewed article that remains subject to further editorial refinement. Nevertheless, the convergence of evidence — across two independent mouse models, multiple omics technologies, and human tissue and fluid samples — makes a compelling case that the cells once dismissed as passive insulation around nerve fibers may hold a key to understanding, and perhaps one day slowing, one of the world’s most common neurodegenerative diseases.

Subject of Research: Disease-associated oligodendrocytes and interleukin 33–ST2 immune signaling in Parkinson's disease

Article Title: Spatial multi-omics reveals disease-associated oligodendrocytes and metabolic dysregulation in male Parkinson’s disease mouse models

Article References: Zhu, Z., Xu, Z., Chen, M., Ding, L., Feng, D., Liang, F., Shu, H., Su, Z., Huang, X., Zhu, X., Liang, X., Huang, S., Xu, P., & Zhang, W. (2026). Spatial multi-omics reveals disease-associated oligodendrocytes and metabolic dysregulation in male Parkinson’s disease mouse models. Nature Communications. https://doi.org/10.1038/s41467-026-78051-5

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78051-5

Keywords: Parkinson's disease, oligodendrocytes, interleukin 33, ST2 receptor, alpha-synuclein, spatial transcriptomics, spatial metabolomics, microglia, substantia nigra, lipid metabolism, glutamate signaling, neurodegeneration